Viridian Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
/ 
Frequently asked questions
To buy Viridian Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Viridian Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Viridian Therapeutics Inc. is VRDN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Viridian Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade Viridian Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Viridian Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Viridian Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Viridian Therapeutics Inc..